News

Amgen leads Series B investment in Bozeman, Montana’s SiteOne Therapeutics, Montana’s Next Frontier’s 1st Investment

January 6, 2017 /

MATR Sponsor (view all)


The MDT Disadvantaged Business Enterprise (DBE) Program encourages and supports the participation of companies owned and controlled by socially and economically disadvantaged individuals in transportation contracts.

Today, SiteOne Therapeutics http://siteonetherapeutics.com/ announced the successful closing of its Series B led by Amgen, with follow on investment from Next Frontier and other insiders. In addition, the company signed a research and development agreement with Amgen combining SiteOne’s experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen’s neuroscience capabilities.

In July 2015, Next Frontier http://www.nextfrontiercapital.com/ , as our first ever investment, led SiteOne’s Series A. The company, with HQ in Bozeman and offices in San Francisco, is developing non-opioid analgesics; the ability to treat chronic pain without habit forming side effects.

Will Price
Managing Partner, Next Frontier Capital

Full Story: https://www.linkedin.com/pulse/amgen-leads-series-b-investment-siteone-therapeutics-next-will-price

Additional Next Frontier News: https://www.linkedin.com/today/author/0_0_R5V37hQ3A1nmXIX_AEAM?trk=vsrp_people_res_infl_recent

MATR Supporters (view all)


Great Falls trade area. Competitive for food, ag, bioprocessing, energy, and support. Closest U.S. metro area to Calgary. Untame Your Entrepreneurial Spirit!

Montana Technology Innovation Partnership (MTIP)- Promoting Technology Commercialization in the State of Montana.

Bozeman is a rapidly growing city with a high quality of life in part due to the easy access to the outdoors, burgeoning tech industry, and cultural experiences it offers.
Posted in:

Sorry, we couldn't find any posts. Please try a different search.

Leave a Comment

You must be logged in to post a comment.